FY2029 EPS Estimates for IceCure Medical Cut by Analyst

IceCure Medical Ltd. (NASDAQ:ICCM) – Analysts at Brookline Capital Markets dropped their FY2029 earnings estimates for IceCure Medical in a report released on Tuesday, May 12th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of $0.05 per share for the year, down from their previous forecast of $0.08. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.12) per share.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 222.27%. The company had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.34 million.

Several other brokerages have also recently issued reports on ICCM. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Alliance Global Partners began coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Price Performance

Shares of NASDAQ ICCM opened at $0.24 on Thursday. IceCure Medical has a 1 year low of $0.22 and a 1 year high of $1.40. The company’s 50-day moving average is $0.42 and its 200 day moving average is $0.58. The stock has a market capitalization of $19.24 million, a P/E ratio of -0.99 and a beta of 0.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of IceCure Medical in the fourth quarter worth approximately $39,000. Jane Street Group LLC bought a new position in shares of IceCure Medical in the fourth quarter worth approximately $67,000. Finally, Concurrent Investment Advisors LLC bought a new position in shares of IceCure Medical in the fourth quarter worth approximately $48,000. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.